FGF-23 and PTH levels in patients with acute kidney injury: A cross-sectional case series study.
FGF-23 and PTH levels in patients with acute kidney injury: A cross-sectional case series study.
复制标题
DOI：
10.1186/2110-5820-1-21
复制
发表时间：
2011-06-14
影响因子：
8.1
通讯作者：
Liu KD
中科院分区：
文献类型：
--
作者：
Zhang M;Hsu R;Hsu CY;Kordesch K;Nicasio E;Cortez A;McAlpine I;Brady S;Zhuo H;Kangelaris KN;Stein J;Calfee CS;Liu KD
Fibroblast growth factor-23 (FGF-23), a novel regulator of mineral metabolism, is markedly elevated in chronic kidney disease and has been associated with poor long-term outcomes. However, whether FGF-23 has an analogous role in acute kidney injury is unknown. The goal of this study was to measure FGF-23 levels in critically ill patients with acute kidney injury to determine whether FGF-23 levels were elevated, as in chronic kidney disease. Plasma FGF-23 and intact parathyroid hormone (PTH) levels were measured in 12 patients with acute kidney injury and 8 control subjects. FGF-23 levels were significantly higher in acute kidney injury cases than in critically ill subjects without acute kidney injury, with a median FGF-23 level of 1948 RU/mL (interquartile range (IQR), 437-4369) in cases compared with 252 RU/mL (IQR, 65-533) in controls (p = 0.01). No correlations were observed between FGF-23 and severity of acute kidney injury (defined by the Acute Kidney Injury Network criteria); among patients with acute kidney injury, FGF-23 levels were higher in nonsurvivors than survivors (median levels of 4446 RU/mL (IQR, 3455-5443) versus 544 RU/mL (IQR, 390-1948; p = 0.02). Severe hyperparathyroidism (defined as intact PTH >250 mg/dL) was present in 3 of 12 (25%) of the acute kidney injury subjects versus none of the subjects without acute kidney injury, although this result did not meet statistical significance. We provide novel data that demonstrate that FGF-23 levels are elevated in acute kidney injury, suggesting that FGF-23 dysregulation occurs in acute kidney injury as well as chronic kidney disease. Further studies are needed to define the short- and long-term clinical effects of dysregulated mineral metabolism in acute kidney injury patients.
登录
查看更多内容
DOI：
10.2215/cjn.05420709
发表时间：
2010-02-01
影响因子：
9.8
作者：
Oliveira, Rodrigo B.;Cancela, Ana L. E.;Moyses, Rosa M. A.
通讯作者：
Moyses, Rosa M. A.
DOI：
10.1056/nejmoa0706130
发表时间：
2008-08-07
期刊：
The New England journal of medicine
影响因子：
--
作者：
Gutiérrez OM;Mannstadt M;Isakova T;Rauh-Hain JA;Tamez H;Shah A;Smith K;Lee H;Thadhani R;Jüppner H;Wolf M
通讯作者：
Wolf M
影响因子：
13.6
作者：
Ishani, Areef;Xue, Jay L.;Collins, Allan J.
通讯作者：
Collins, Allan J.
影响因子：
6.1
作者：
Jean, Guillaume;Terrat, Jean-Claude;Chazot, Charles
通讯作者：
Chazot, Charles
DOI：
10.1038/ki.2009.188
发表时间：
2009-08-01
期刊：
Kidney international. Supplement
影响因子：
--
作者：
通讯作者：
--